February 21, 2018 / 9:13 PM / 3 months ago

BRIEF-Vertex Initiates Late Stage Study Of Treatment Combination For Cystic Fibrosis

Feb 21 (Reuters) - Vertex Pharmaceuticals Inc:

* VERTEX INITIATES FIRST PHASE 3 STUDY OF VX-659, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS

* VERTEX PHARMACEUTICALS INC - GLOBAL PHASE 3 STUDY TO ENROLL 360 PATIENTS WITH ONE F508DEL MUTATION AND ONE MINIMAL FUNCTION MUTATION

* VERTEX - PHASE 3 VX-659 STUDY DESIGNED TO SUPPORT SUBMISSION OF NDA IN U.S. BASED ON 4-WEEK PRIMARY EFFICACY ENDPOINT AND 12-WEEK SAFETY DATA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below